ChromoGenics AB reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 2.23 million compared to SEK 5.98 million a year ago. Revenue was SEK 3.08 million compared to SEK 10.27 million a year ago. Net loss was SEK 10.96 million compared to SEK 11.37 million a year ago. Basic loss per share from continuing operations was SEK 3.31 compared to SEK 32 a year ago. Diluted loss per share from continuing operations was SEK 3.31.
For the nine months, sales was SEK 13.01 million compared to SEK 18.63 million a year ago. Revenue was SEK 16.14 million compared to SEK 22.83 million a year ago. Net loss was SEK 35.91 million compared to SEK 44.54 million a year ago. Basic loss per share from continuing operations was SEK 16.66 compared to SEK 151.59 a year ago. Diluted loss per share from continuing operations was SEK 16.66 compared to SEK 151.59 a year ago.